Doctors Rebecca Brown and Elif Oral are already members of the AELIP expert committee.
Rebecca Brown graduated from Rice Mayo Medical School, where she completed her pediatric studies.
Rebeca is a resident at the Rainbow Babies and Children's hospital.
In 2005, he started at the National Institutes of Health with a grant in pediatric endocrinology and has remained in the NIH intramural research program since then.
In 2015, she became the first Lasker researcher in the NIDDK.
His research focuses on pathophysiology and clinical therapeutics for rare diseases disorders of extreme insulin resistance, including lipodystrophy and insulin receptor dysfunction, as well as the mechanisms of action of leptin to improve metabolic disease.
Elif Oral is a Professor in the Division of Metabolism, Endocrinology and Diabetes (MEND) at the University of Michigan and a member of the American Society for Clinical Research (ASCI).
Professor Elif, completed her medical education in her home country Turkey and more specifically at the University of Istanbul.
In 1996, he completed his residency in Internal Medicine at the Sinai Hospital in Detroit (Michigan).
He then completed a Scholarship in Endocrinology, Metabolism and Diabetes at the National Institutes of Health, where he also chose to remain a Senior Fellow under the tutelage of Dr. Simeon Taylor and Phillip Gorden in the Diabetes Branch of NIDDK.
Since joining the University of Michigan in 2002 as an Assistant Professor of Medicine, he combines his responsibilities as a professor, with the aforementioned.
Elif also completed a Master in Clinical Sciences Research Design and Biostatistics at the School of Public Health.
He earned his position in Michigan in 2011.
Dr. Oral's research focuses on the importance of adipocytes in human metabolism and hormone adipocytes such as leptin.
This health professional is also known for her work demonstrating the efficacy of leptin in infrequent lipodystrophic syndromes.
They are currently working on the development of additional therapies and on improving the treatment algorithms for several lipodystrophies, trying to improve the accuracy of the clinical results.
In addition to her role as a doctor, educator, and researcher, the doctor is also director of three unique clinical programs at Michigan Medicine:
Atypical Diabetes Program, Post Bariatric Surgery, Program and Obesity and Metabolic Disorders
With these major additions, the AELIP committee of experts has, for the first time, two professionals from the US who work in the field of Lipodystrophies, giving more prestige to this resource that AELIP implements to improve the quality of life of people and families living with a Lipodystrophy in the world.
AELIP reminds that in order to be part of this committee, the criteria and requirements that can be found in the following link must be met: